Denali Therapeutics (DNLI) vs MBX Biosciences (MBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MBX Biosciences (MBX) has outperformed Denali Therapeutics (DNLI) over the past year, gaining 245.2% versus a gain of 28.6%. Denali Therapeutics is the larger company by market cap ($3.06 billion vs $2.63 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNLI | MBX |
|---|---|---|
| Share price | $19.16 | $54.54 |
| Market cap | $3.06B | $2.63B |
| 1-day change | -0.62% | -4.18% |
| YTD return | +16.05% | +72.92% |
| 1-year return | +28.59% | +245.19% |
| 5-year return | -57.95% | — |
| EPS (TTM) | $-2.82 | $-2.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.30 | $72.64 |
| 52-week low | $13.75 | $12.94 |
| Distance from 52-week high | -29.82% | -24.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.20% | +72.90% |
| Average volume | 1.61M | 556.72K |
| Shares outstanding | 159.85M | 48.16M |
| Employees | 503 | 63 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed DNLI by 216.6 percentage points over the past year.
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Healthcare · Biotechnology · 503 employees
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Healthcare · Biotechnology · 63 employees
DNLI vs MBX FAQ
Which is bigger, Denali Therapeutics or MBX Biosciences?
Denali Therapeutics (DNLI) is larger, with a market capitalization of $3.06B compared with $2.63B for MBX Biosciences (MBX).
Which stock has performed better over the past year, DNLI or MBX?
MBX returned +245.19% over the past 12 months, compared with +28.59% for DNLI (price return, excluding dividends). Past performance does not predict future results.
Are Denali Therapeutics and MBX Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.